Globally, diabetes represents a considerable burden on healthcare systems, with a global age-standardized total prevalence of 6.1% in 2021. Moreover, the global burden of diabetes is predicted to increase due to rising incidences of type 1 and type 2 diabetes, the aging of the world population, and comorbidities. This increase is expected to result in a further rise in hospitalizations among individuals with diabetes, significantly impacting patients' quality of life, health status, and outcomes.
Hypertension affects 1 in 3 adults worldwide. The number of individuals affected by hypertension doubled between 1990 and 2019, rising from 650 million to 1.3 billion. This common and deadly condition can lead to stroke, heart attack, heart failure, kidney damage, and other diseases. Alarmingly, only 21% of people with hypertension have it under control.
Global evidence suggests that patients with diabetes and hypertension are at a higher risk of cardiovascular disease due to several shared pathophysiological pathways. While various mechanisms have been proposed, the underlying relationship and the effects of novel therapies remain insufficiently explored, highlighting the need for further research
This Research Topic aims to provide insights into various aspects of the connections between diabetes and hypertension, presenting recent developments in management strategies, associated outcomes, prescription of antihypertensive drugs, and the potential pathological mechanisms underlying these relationships.
Authors are invited to submit papers presenting innovative findings on the mechanisms underlying the relationship between diabetes and hypertension. While articles should cover a range of subjects, they are not limited to the following:
- Pathophysiological aspects of the relationship between diabetes and hypertension
- Cardiovascular complications and outcomes in patients with type 1 and type 2 diabetes and hypertension
- Determinants and outcomes related to antihypertensive therapy in patients with type 1 and type 2 diabetes
Globally, diabetes represents a considerable burden on healthcare systems, with a global age-standardized total prevalence of 6.1% in 2021. Moreover, the global burden of diabetes is predicted to increase due to rising incidences of type 1 and type 2 diabetes, the aging of the world population, and comorbidities. This increase is expected to result in a further rise in hospitalizations among individuals with diabetes, significantly impacting patients' quality of life, health status, and outcomes.
Hypertension affects 1 in 3 adults worldwide. The number of individuals affected by hypertension doubled between 1990 and 2019, rising from 650 million to 1.3 billion. This common and deadly condition can lead to stroke, heart attack, heart failure, kidney damage, and other diseases. Alarmingly, only 21% of people with hypertension have it under control.
Global evidence suggests that patients with diabetes and hypertension are at a higher risk of cardiovascular disease due to several shared pathophysiological pathways. While various mechanisms have been proposed, the underlying relationship and the effects of novel therapies remain insufficiently explored, highlighting the need for further research
This Research Topic aims to provide insights into various aspects of the connections between diabetes and hypertension, presenting recent developments in management strategies, associated outcomes, prescription of antihypertensive drugs, and the potential pathological mechanisms underlying these relationships.
Authors are invited to submit papers presenting innovative findings on the mechanisms underlying the relationship between diabetes and hypertension. While articles should cover a range of subjects, they are not limited to the following:
- Pathophysiological aspects of the relationship between diabetes and hypertension
- Cardiovascular complications and outcomes in patients with type 1 and type 2 diabetes and hypertension
- Determinants and outcomes related to antihypertensive therapy in patients with type 1 and type 2 diabetes